Abstract

RadNet will release its fiscal first-quarter 2026 results on May 11, 2026 Pre-Market; the preview highlights consensus expectations for higher revenue alongside seasonal margin pressure and a negative adjusted EPS print typical for the period.

Market Forecast

For the current quarter, the market projects RadNet’s revenue at 557.97 million US dollars, implying 25.89% year-over-year growth; EBIT is forecast at 5.42 million US dollars, and adjusted EPS is expected to be -0.20, with year-over-year growth for EPS at -50.95%. The forecast points to mixed profitability with potential pressure on adjusted EPS; expectations imply continued top-line momentum.

RadNet’s core imaging services remain the main business driver, with management continuing to emphasize volume growth and expanded capacity across markets. AI-enabled diagnostics and associated workflow solutions are cited as a promising growth area, with traction expected to continue this quarter.

Last Quarter Review

In the previous quarter, RadNet reported revenue of 547.71 million US dollars, a gross profit margin of 35.47%, GAAP net profit attributable to the parent company of -0.60 million US dollars, a net profit margin of -0.11%, and adjusted EPS of 0.24, with year-over-year growth of 9.09%.

A key highlight was revenue outperformance versus internal and external expectations, reflecting continued patient volume growth and expanded service offerings. The main business continued to be led by imaging services, generating 1.91 billion US dollars annually from service fees and 125.54 million US dollars from capitation arrangements, with the latest quarter benefiting from strong schedules and a favorable mix.

Current Quarter Outlook (with major analytical insights)

Main imaging services

The central driver this quarter remains the company’s imaging services footprint, which historically experiences seasonal softness early in the year but has been offset by secular demand growth and capacity additions. The projected revenue of 557.97 million US dollars suggests continued throughput, supported by referral growth and network optimization. Operating leverage will be sensitive to staff productivity and scan mix, particularly in MRI and advanced modalities that carry higher reimbursement but longer exam times.

AI and digital solutions

AI-enabled diagnostics and workflow optimization present a meaningful medium-term margin lever, even if near-term EPS remains negative due to seasonal factors. The focus this quarter is on scaling algorithms that prioritize triage and reduce radiologist turnaround time, which can expand capacity without proportionate labor costs. As payers emphasize quality metrics and faster reporting, these tools can support revenue capture and improve denials management, aiding both top-line and cash cycle metrics.

Key stock price swing factors

Margin cadence is the principal swing factor, with investors scrutinizing whether gross margin can hold near the mid-30% range despite wage inflation and modality mix shifts. Utilization trends and appointment backlogs will be watched for signs of sustainable volume throughput into late spring, a precondition for earnings normalization in the second and third quarters. Reimbursement updates and managed care negotiations remain an overhang; any commentary on rate floors or contract wins could recalibrate expectations for second-half earnings power.

Analyst Opinions

Bullish opinions dominate among recently published views. Barclays reiterated a Buy rating with an 86.00 US dollars price target, emphasizing durable volume growth, strengthening AI adoption, and operating efficiencies. Raymond James also maintained a Buy stance, highlighting strategic expansion and AI execution as catalysts for margin improvement and sustained revenue growth. The preponderance of positive ratings indicates a favorable institutional view going into the print, with emphasis on top-line resilience and a pathway to improved profitability over the course of the year.